公司資料

Ovid Therapeutics 股價、新聞與催化劑

股票代碼:: OVID
交易所:: NASDAQ
產業:: Biopharma
所在地:: United States

股票表現

2.80 USD (+2.19%)

收盤價

最後更新: 2026年8月21日

448M USD

市值

股價為何變動

As of Aug 21, 2026, OVID closed up 2.19% at $2.80. No new same-company headline was identified in the current news window.

公司概覽

Neurological Small-Molecule Company

Ovid Therapeutics develops medicines for epilepsies and other intractable brain disorders.

OV329

OV329 is a next-generation GABA aminotransferase inhibitor being developed for focal-onset seizures, tuberous sclerosis complex seizures, and infantile spasms.

OV4071

OV4071 is an oral direct activator of the potassium-chloride cotransporter KCC2 and is intended to restore inhibitory neuronal signaling.

未來催化劑

Initiation of the OV4071 ketamine-challenge study in the second half of 2026.
Initiation of a Phase 2 proof-of-concept study of OV4071 in acute schizophrenia in 2027.